Eden Biologics, Inc.

JHL Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing high-quality biologics, particularly biosimilars, to meet global healthcare needs. Founded in 2012, JHL Biotech, Inc. is headquartered in Zhubei, Taiwan.

The company specializes in the production of biosimilars and has undergone strategic developments to enhance its operations. Notably, JHL Biotech became publicly listed on the Taiwan Emerging Stock Board on September 17, 2015. The company has been involved in five different investment deals, with the latest funding round being a SERIES C amounting to USD 45. 60 mn, supported by investors such as Liwick Investment Management, Milestone Capital, and YuanBio Venture.

JHL Biotech, Inc. specializes in developing biosimilar products aimed at treating various medical conditions. Their portfolio includes monoclonal antibodies and other biologics, intended to provide affordable treatment options while maintaining high standards of quality. The company primarily operates in the biopharmaceutical sector, targeting global markets in North America, Europe, and Asia.

JHL Biotech, Inc. generates revenue through the commercialization of its biosimilar products, leveraging partnerships and collaborations within the biopharmaceutical industry. Their business model focuses on creating innovative therapies that cater to the needs of healthcare providers and patients, ensuring a consistent revenue stream as they expand their market presence. JHL Biotech, Inc.

plans to launch new biosimilars to broaden its product offerings, with specific timelines for release to be determined based on regulatory processes. The company aims to expand into European and North American markets, enhancing its geographical footprint by 2025. The recent funding from the SERIES C round will be strategically allocated to support these initiatives, facilitating research and development efforts as well as marketing strategies to penetrate these new regions.